Radiopharm Theranostics Ltd
RADXDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
177Lu-BetaBart
Castration-Resistant Prostate Cancer (CRPC)
RAD101 (18F-FPIA)
Brain Metastases From Solid Tumors
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
177Lu-BetaBart | Phase 2 | Castration-Resistant Prostate Cancer (CRPC) | - | - |
RAD101 (18F-FPIA) | Phase 2 | Brain Metastases From Solid Tumors | - | - |
Frequently asked questions
What is in Radiopharm Theranostics Ltd's drug pipeline?→
CatalystAlert tracks 2 drug candidates in Radiopharm Theranostics Ltd's (RADX) pipeline across Phase 2. Its lead program is 177Lu-BetaBart (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Radiopharm Theranostics Ltd's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Radiopharm Theranostics Ltd (RADX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track RADX biotech catalysts?→
Add RADX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Radiopharm Theranostics Ltd's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.